Table 3. Estimated linear trends in vaccination coverage by age 24 months, National Immunization Survey-Child, United States, 2013-2017

		Monthly Birth Cohorts (A) January 2012–January 2016			Monthly Birth Cohorts (B) January 2014–January 2016		
Vaccine/Dose	_	Estimate	Lower CI	Upper CI	Estimate	Lower CI	Upper CI
DTaP*							
≥3 doses	Baseline coverage [†]	95.18	94.54	95.83	93.28	90.42	96.14
	12-month change§	-0.29	-0.59	0.01	0.30	-0.65	1.25
≥4 doses	Baseline coverage	82.49	81.07	83.91	81.71	75.16	88.26
	12-month change	-0.55	-1.20	0.10	-0.23	-2.42	1.96
Poliovirus (≥3 doses)	Baseline coverage	93.45	92.71	94.20	89.66	85.79	93.52
	12-month change	-0.17	-0.52	0.18	1.05	-0.21	2.31
MMR (≥1 dose)	Baseline coverage	91.34	90.33	92.34	93.46	89.59	97.33
	12-month change	-0.11	-0.58	0.35	-0.88	-2.19	0.43
Hib [¶]							
Primary series	Baseline coverage	94.56	93.81	95.30	93.06	90.02	96.10
	12-month change	-0.50	-0.86	-0.14	-0.07	-1.09	0.95
Full series	Baseline coverage	81.53	80.19	82.88	81.97	76.13	87.81
	12-month change	-0.51	-1.13	0.11	-0.65	-2.61	1.31
НерВ							
≥3 doses	Baseline coverage	93.29	92.37	94.21	89.87	86.19	93.56
	12-month change	-0.53	-0.97	-0.09	0.58	-0.65	1.80
Birth dose**	Baseline coverage	72.67	71.14	74.20	65.40	60.05	70.76
	12-month change	0.58	-0.10	1.26	2.97	1.22	4.73
Varicella (≥1 dose)	Baseline coverage	90.69	89.66	91.72	90.73	86.56	94.90
	12-month change	-0.05	-0.53	0.42	-0.14	-1.54	1.26
PCV							
≥3 doses	Baseline coverage	93.42	92.62	94.22	92.30	88.25	96.35
	12-month change	-0.18	-0.55	0.19	0.19	-1.17	1.55
≥4 doses	Baseline coverage	82.50	80.97	84.03	83.61	75.96	91.26
	12-month change	0.00	-0.69	0.68	-0.33	-2.88	2.22
НерА							
≥1 doses	Baseline coverage	83.14	82.00	84.28	83.05	78.76	87.35
	12-month change	0.44	-0.07	0.96	0.46	-0.98	1.90
≥2 doses	Baseline coverage	39.56	37.77	41.34	45.29	38.79	51.79
	12-month change	1.13	0.30	1.97	-0.76	-2.95	1.44
≥2 doses (by 35 months) ^{††}	Baseline coverage	75.26	72.34	78.19	85.76	68.93	102.60
	12-month change	-0.42	-1.96	1.12	-4.39	-10.77	1.98
Rotavirus (by 8 months)§§	Baseline coverage	71.87	70.17	73.57	73.47	66.87	80.07
	12-month change	0.68	-0.09	1.45	0.15	-2.08	2.38
Combined 7-vaccine series	Baseline coverage	69.44	67.67	71.20	69.82	61.69	77.96
	12-month change	-0.27	-1.07	0.53	-0.33	-3.05	2.40

Abbreviations: CI = confidence interval; DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = Haemophilus influenzae type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine

Bolded estimates of 12-month change in coverage are statistically significant at p<0.05, where the 95% CI does not contain zero.

- * Includes children who might have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.
- † Estimated vaccination coverage for the oldest monthly birth cohort included in the linear regression analysis (the estimated intercept for the fitted linear regression line).

[§] Percentage point change in coverage over 12 months of birth, estimated as the per-month-of-birth slope of the fitted regression line*12.

[¶] Hib primary series: receipt of ≥2 or ≥3 doses, depending on the product type received. Full series: receipt of ≥3 or ≥4 doses, depending on product type received (primary series and booster dose).

^{**} The hepatitis birth dose (one dose of HepB administered between birth and age 3 days) was assessed by age 3 days. Estimates for the group A monthly birth cohorts are based on data from children born January 2012 through May 2016. Estimates for the group B monthly birth cohorts are based on data from children born January 2014 through May 2016.

^{††} ≥2 doses of HepA vaccine was also assessed at 35 months, since a child could follow the recommended schedule and still receive vaccine at this age. Estimates for the group A monthly birth cohorts are based on data from children born January 2012 through February 2015. Estimates for the group B monthly birth cohorts are based on data from children born January 2014 through February 2015.

^{§§} Rotavirus vaccine was assessed at 8 months since the age at vaccination should not exceed 8 months. Estimates for the group A monthly birth cohorts are based on data from children born January 2012 through May 2016. Estimates for the group B monthly birth cohorts are based on data from children born January 2014 through May 2016.

11 The combined 7-vaccine series includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of

Hib (≥3 or ≥4 doses, depending on product type of vaccine), ≥3 doses of HepB, ≥1 dose of varicella vaccine, and ≥4 doses of PCV.